

Tanzania
Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Tanzania				
2. Routine vaccines grant number: 1820-TZA-19b-X Routine vaccine introduction grant: 18-TZA-08f-Y Multi age cohort vaccines grant number: 19-TZA-19c-X Multi age cohort operation costs grant number: 19-TZA-19e-Y				
3. Date of Decision Letter: 29 January 2018				
4. Date of the Partnership Framework Agreement: 01 July 2013				
5. Programme title: New Vaccine Support (NVS), HPV Routine with multi age cohort in the year of introduction				
6. Vaccine type: HPV				
7. Requested product presentation and formulation of vaccine: <i>HPV Quadrivalent, 1 dose(s) per vial, LIQUID</i>				
8. Programme duration¹: 2018 - 2020				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2018	2019	2020	Total ²
Programme Budget (Routine) (US\$)	US\$7,558,000	US\$6,250,500	US\$6,422,000	US\$20,230,500
Multi Age Cohort Support (US\$)		US\$ 30,208,500		US\$ 30,208,500
Total (\$US)	US\$7,558,000	US\$36,459,000	US\$6,422,000	US\$50,439,000
10. Vaccine introduction grant: US\$ 1,719,890				
11. Operational support for Multi Age Cohort : US\$ 2,224,858 (for information – the approval will be communicated at a later stage and disbursed in 2019)				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)³

Type of supplies to be purchased with Gavi funds in each year (Routine)	2018
Number of HPV vaccines doses	1,663,500
Annual Amounts (US\$)	US\$ 7,558,000

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations: Reference code: 1820-TZA-19b-X-C
According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. ⁴

Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	76,600	63,400	64,400
Value of vaccine doses (US\$)	344,693	285,060	
Total co-financing payments (US\$) (including freight)	US\$348,500	US\$288,000	US\$296,000

16. Additional reporting requirements:

Reports other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May of each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

³ This is the amount that Gavi has approved.

⁴ Co-Financing applies only to the routine cohort. (Multi age cohort is fully financed by Gavi)

17. Financial clarifications: Not applicable
18. Other conditions: Not applicable

On behalf of Gavi

Signed by,



Hind Khatib-Othman
Managing Director, Country Programmes
29 January 2018